TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: interleukin-6 (IL-6) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NYHA stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flow-mediated dilation (FMD) of brachial artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Barthel scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients with undetectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Annual decline of PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Formulated a psychosocial distress screening policy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Started screening in more than one clinic/population
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Started auditing health records for documentation of screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: phosphorylated protein signaling in myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mitochondrial respiration in leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum cardiac troponin I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiac death, non-fatal myocardial infarction and ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Live birth at term
Endpoint domain: Mortality/survival
Primary endpoint: Response to treatment (50% reduction in VAS-score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression levels of GST and CYP enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer suicide threats
Endpoint domain: Adverse events/effects
Primary endpoint: Lowered likelihood of future suicide attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Lumbar spine BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Femoral neck BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in supragingival plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day readmission rates
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: percentage of patients receiving appropriate antibiotic prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return rate of HPV self-test
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection of oncogenic HPV type
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Satisfaction with self-testing process
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alanine Aminotransferase (ALT) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver function outcomes
Primary endpoint: Mean Physical Activity (MPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death, recurrent MI and unstable angina
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: methacholine chloride PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of children vaccinated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum P. aeruginosa density reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Uterine Fibroid Symptom-Quality of Life (UFS-QOL) score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Health-Related Quality of Life (HRQOL) score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Smoking uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive outcome of pain drawings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCS change at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vitality change at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Social Functioning change at Week 8
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Confirmed cardiogenic shock events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confirmed CHF events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major catheter-related infections (CRIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter-related bloodstream infections
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal vessel diameter change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: plasma clearance of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intranasal bioavailability of oxycodone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased severity of adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: elevation of TGFβ1 and TGFβ3 proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of individuals with a decrease of >30% in plasma NT-proBNP from baseline to Day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative compression depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IH
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of peristomal infection within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter change within 180 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diameter of spleen vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Complications after paracentesis
Endpoint domain: Adverse events/effects
Primary endpoint: final wake time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mtDNA copy number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBC ATP synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between conventional longitudinal change and patient perceived change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in free thyroxine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in total testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Aggressiveness (anger, violent feelings, irritability)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resolution of ultrasonographic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in IIEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in frequency of penetration and maintained erection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial plasma bupivacaine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of entropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal laxity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benefit to IADL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benefit to reasoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Benefit to VL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of intramuscular (IM) injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Lung Information Needs Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Activities of daily living scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: VEGF immunoreactivity intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEGF mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate (50% or greater reduction in HAM-D score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sexual function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SCORAD improvement in the head and neck area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Assessment of Constipation Symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Monthly Breast Self-Examination (BSE) reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monthly Testicular Self-Examination (TSE) reporting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prostatitis related pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Homeostasis model assessment (HOMA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of WOMAC20 responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of WOMAC50 responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h average blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total repetitions performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of fatal CHD events
Endpoint domain: Mortality/survival
Primary endpoint: Motor impairment on the FMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional ability on the MAL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with normal alanine aminotransferase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: rate of sustained response 6 months after the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newly developed antidrug antibodies (ADA)
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin-treated hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Induction of TNF‐α, IL‐1β, IL‐6, IL‐8 and IL‐10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vitamin C intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum enzyme concentrations (AST, ALT, GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Healing rate of teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes-related distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-care adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Utilization of LLITN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular filling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: upper extremity motor recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) for total platinum in ascitic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life time for the elimination phase of total platinum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of high-dose DDP therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Mean terminal half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recumbent esophageal acid exposure (EAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Seroprotection rates for H1N1, H3N2, and influenza B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bone loss at the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean physical working capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occupational adjustment score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: AF-related inappropriate shocks
Endpoint domain: Adverse events/effects
Primary endpoint: Pain scores during retrobulbar placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedation scores during retrobulbar placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborns' soliciting calls
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Crying frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relaxation state onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Globus symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep complaints
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Increase in bone-free lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in serum zinc concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: joint attention improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: joint engagement improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: BMD (Bone Mineral Density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ALP (Alkaline Phosphatase) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: QTcF treatment-placebo differences (DeltaDeltaQTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rates of mortality
Endpoint domain: Mortality/survival
Primary endpoint: median numbers of intensive care unit‐free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventilator‐free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal HIV-1 RNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: new mental health treatment required
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of pain during VAP implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: area under the serum simvastatin concentration-time curve (AUC(0-24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported vision-related functioning (NEI-VFQ-25 composite)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported vision-related functioning (NOS-10 composite)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HCVA recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in telomere length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages of infants with antibody concentrations ≥0.2 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Measurable opsonophagocytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: in-hospital stay duration
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Efficacy of cyclobenzaprine hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to central nervous system
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of SSE plus mobile teledermoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive performance (visuospatial processing)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Attitudes towards patient diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived behavioral control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time of first analgesic request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale at rest and on exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actuarial survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac event free rates
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of skin roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Insulin levels improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-peptide improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in urinary CTX‐II concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in MMP‐3 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: non-HDL-cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor dimensions reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal uptake of hypoxanthine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Segmental lordosis maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjacent segment degeneration progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle thickness (hypertrophy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diarrhea rates
Endpoint domain: Adverse events/effects
Primary endpoint: subjective improvement in post-test scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: objective improvement in post-test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevention of skeletal complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: analgesics demand on the day of the operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-operative nutritional deficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resumption of occupational activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Ability to perform family activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: mean canine movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean COF of brackets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional inpatient treatment required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Accuracy of contouring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for contouring
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: general health perceptions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ADPS from baseline to week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of new-onset VCFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: visual analog scale score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: lumbar spine BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Drug-liking ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing